Forward P/S Multiple: NanoVibronix (NAOV)

NanoVibronix - graphic logo of issuer NAOV

An optimized supply chain and internal reserves minimize procurement disruptions, which is supported by a forward price-to-sales valuation with a metric value of 1.60. NanoVibronix, Inc. (NAOV) is protected by strict FDA regulations and unique WoundWand patents. Business resilience is further bolstered by the development of wearable ultrasound systems for rehabilitation and home use, which expand the company's target markets.

nanovibronix.com - NAOV Market Cap to Projected Revenue (period 07/04/2022 - 12/12/2025)

Summary analytical data breakdowns for NanoVibronix (NAOV)

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Fundamental company analysis:NAOV (NanoVibronix)
Product sample of nanovibronix.com

Amidst a conservative therapeutic ultrasound market and slow insurance approval for procedures, the expected P/S ratio helps assess the justification of NanoVibronix, Inc. (NAOV) market value relative to its potential. This indicator compares current market capitalization with projected revenue, allowing investors to determine the control premium and identify asset overbought conditions as the chart approaches historical extremes.

Who NanoVibronix, Inc. competes with

Price-to-Projected Revenue Ratio Dexcom CGM DXCM|Penumbra Corp (PEN) - Market Cap to Future Revenue Ratio|Novanta Inc - Forward P/S Multiple|HAE (Haemonetics Corporation) - Market Cap to Projected Revenue|INSP: Forward P/S Multiple|Market Cap to Projected Revenue PRCT|CNMD (CONMED Inc.) - Forward P/S Multiple|Pulse Corp (PLSE) - Market Cap to Expected Sales Ratio|Forward P/S Multiple INMD|Forward P/S Multiple picardmedical.com (PMI)|Forward P/S Multiple SRDX (surmodics.com)|Forward P/S Multiple Senseonics Holdings, Inc. SENS|NPCE - Price-to-Projected Revenue Ratio|TCMD: Price-to-Projected Revenue Ratio|SNWV (Sanuwave Health Inc) - Forward Price-to-Revenue Multiple|Projected Price to Revenue Outset Medical OM|ELMD (SmartVest) - Forward P/S Multiple|Market Cap to Future Revenue Ratio LENSAR Inc. LNSR|Price-to-Projected Revenue Ratio AVITA Medical Inc. (RCEL)|Profound Medical Corporation (PROF) - Projected Price to Revenue|Baird Medical Investment Holdings - Forward Price-to-Revenue Multiple|Forward P/S Multiple EDAP Medical EDAP|Apyx Medical Corp - Forward P/S Multiple|Market Cap to Expected Sales Ratio IceCure Medical ICCM|Pulmonx (LUNG) - Price-to-Projected Revenue Ratio|Future Price to Revenue TELA (TELA Bio Corp)|Price-to-Projected Revenue Ratio cytosorbents.com|Forward Price-to-Revenue Multiple Sensus Healthcare, Inc. (SRTS)|Forward P/S Multiple ZYXI|ECOR - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio vicarioussurgical.com RBOT|IINN: Market Cap to Projected Revenue|ICU - Price-to-Projected Revenue Ratio|iridex.com - Price to Expected Revenue Ratio|INBS: Forward P/S Multiple|XAIR (Beyond Air Inc) - Price-to-Projected Revenue Ratio|Price-to-Projected Revenue Ratio Profusa, Inc.|SSKN (strataskinsciences.com) - Price to Expected Revenue Ratio|Forward Price-to-Revenue Multiple GCTK (GlucoTrack Inc.)|Venus Concept - Market Cap to Projected Revenue|Forward P/S Multiple NUWE (Nuwellis Corp)|Forward Price to Sales AEMD|ASXC - Price-to-Projected Revenue Ratio|Projected Price to Revenue Avinger, Inc (AVGR)|BSGM: Forward P/S Multiple|Cutera (CUTR) - Forward P/S Multiple|KNW (Know Labs) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Inari Medical (NARI)|Price-to-Projected Revenue Ratio nevro.com (NVRO)|RSLS (ReShape Lifesciences, Inc.) - Forward Price to Sales|Forward P/S Multiple SILK (Silk Road Medical)